• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LIU Yan, LI Chengye, CAI Xingguang, SUN Lidan, HUANG Wenlong. Synthesis and preliminary anti-diabetic activity evaluation of novel PEGylated GLP-1 receptor agonists[J]. Journal of China Pharmaceutical University, 2018, 49(5): 558-567. DOI: 10.11665/j.issn.1000-5048.20180507
Citation: LIU Yan, LI Chengye, CAI Xingguang, SUN Lidan, HUANG Wenlong. Synthesis and preliminary anti-diabetic activity evaluation of novel PEGylated GLP-1 receptor agonists[J]. Journal of China Pharmaceutical University, 2018, 49(5): 558-567. DOI: 10.11665/j.issn.1000-5048.20180507

Synthesis and preliminary anti-diabetic activity evaluation of novel PEGylated GLP-1 receptor agonists

More Information
  • In order to obtain glucagon-like peptide-1(GLP-1)analogs which can sustainedly control the levels of glucose, 12 derivatives were designed and synthesized by coupling monomethoxy polyethylene glycol(mPEG, with average molecular weights of 350, 550 and 750)to GLP-1 analogs. Preliminary pharmacological activities showed that all compounds retained GLP-1 receptor agonist activities, and the hypoglycemic activity of compound I - 12 was similar to those of Ex-4 and Liraglutide, suggesting I - 12 could be a potential long-acting GLP-1 receptor agonist.
  • [1]
    American Diabetes Association.Diagnosis and classification of diabetes mellitus[J].Diabetes Care,2014,37(Suppl 1):S81-90.
    [2]
    Kerner W,Bruckel J.Definition,classification and diagnosis of diabetes mellitus[J].Exp Clin Endocrinol Diabetes,2014,122(7):384-386.
    [3]
    Kimachi K,Miyoshi H.Infectious disease associated with diabetes mellitus-mechanisms,classification,diagnosis and therapy[J].Nihon Rinsho,2012,70(Suppl 5):507-510.
    [4]
    Hori S.Chronic complications due to diabetes mellitus:diabetic retinopathy-classification,diagnosis,treatment[J].Nihon Rinsho,2002,60(Suppl 10):147-154.
    [5]
    Guariguata L,Whiting DR,Hambleton I,et al.Global estimates of diabetes prevalence for 2013 and projections for 2035[J].Diabetes Res Clin Pract,2014,103(2):137-149.
    [6]
    Manandhar B,Ahn JM.Glucagon-like peptide-1(GLP-1)analogs:recent advances,new possibilities,and therapeutic implications[J].J Med Chem,2015,58(3):1020-1037.
    [7]
    Smits MM, Tonneijck L, Muskiet MH, et al. Gastrointestinal actions of glucagon-like peptide-1-based therapies:glycaemic control beyond the pancreas[J].Diabetes Obes Metab,2016,18(3):224-235.
    [8]
    Craig CM,Liu LF,Deacon CF,et al.Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia[J].Diabetologia,2017,60(3):531-540.
    [9]
    Vinué,Navarro J,Herrerocervera A,et al.The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype[J].Diabetologia,2017,60(9):1801-1812.
    [10]
    Pham H,Hui H,Morvaridi S,et al.A bitter pill for type 2 diabetes?The activation of bitter taste receptor TAS2R38 can stimulate GLP-1 release from enteroendocrine L-cells[J].Biochem Biophys Res Commun,2016,475(3):295-300.
    [11]
    Brubaker PL.Species-dependent mechanisms regulating glucose-dependent GLP-1 secretion [J]? Diabetes,2017,66(8):2063-2065.
    [12]
    Youn YS,Chae SY,Lee S,et al.Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment:insulinotropic activity,glucose-stabilizing capability,and proteolytic stability[J].Biochem Pharmacol,2007,73(1):84-93.
    [13]
    Lee S,Youn YS,Lee SH,et al.PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice[J].Diabetologia,2006,49(7):1608-1611.
    [14]
    Chi Y,Zhang H,Huang W,et al.Microwave-assisted solid phase synthesis,PEGylation,and biological activity studies of glucagon-like peptide-1(7-36)amide[J].Bioorg Med Chem,2008,16(16):7607-7614.
    [15]
    Veronese FM,Pasut G.PEGylation,successful approach to drug delivery[J].Drug Discov Today,2005,10(21):1451-1458.
    [16]
    Han J,Huang X,Sun L,et al.Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity[J].Biochem Pharmacol,2013,86(2):297-308.
    [17]
    Han J,Sun L,Chu Y,et al.Design,synthesis,and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates[J].J Med Chem,2013,56(24):9955-9968.
  • Related Articles

    [1]JIANG Ning, ZHANG Shuangjian, ZHU Jing, SHANG Jing, GAO Xiangdong. Purification, identification and hypoglycemic activity in vitro of a novel peptide from red deer antler[J]. Journal of China Pharmaceutical University, 2016, 47(3): 363-367. DOI: 10.11665/j.issn.1000-5048.20160320
    [2]LIU Yan, WANG Tingting, CHEN Li. Synthesis and antitumor activity of isosteviol derivatives[J]. Journal of China Pharmaceutical University, 2016, 47(1): 48-53. DOI: 10.11665/j.issn.1000-5048.20160106
    [3]HU Kun, ZHOU Anfei, JIANG Hefei, XU Yuanyuan, HUANG Qianhui, YANG Jie, CHEN Xin, REN Jie. Synthesis and antitumor activities of podophyllotoxin derivatives[J]. Journal of China Pharmaceutical University, 2014, 45(1): 33-38. DOI: 10.11665/j.issn.1000-5048.20140105
    [4]WANG Jiajia, LIU Wei, ZHU Jing, XU Jinnan, GAO Xiangdong. Hypoglycemic activity of a polysaccharide from the roots of Arctium lappa L.[J]. Journal of China Pharmaceutical University, 2013, 44(5): 455-459. DOI: 10.11665/j.issn.1000-5048.20130514
    [5]XING Junhao, ZHANG Yuan, HU Xiaowen, ZHOU Jinpei, ZHANG Huibin. Synthesis and factor Xa inhibitory activity of apixaban derivatives[J]. Journal of China Pharmaceutical University, 2013, 44(4): 289-295. DOI: 10.11665/j.issn.1000-5048.20130401
    [6]QIU Jing-ying, HUANG Zheng-ming, PAN Wei-dong, CAO Pei-xue, LIANG Guang-yi. Synthesis and anti-hepatitis B virus activities of Matijin-Su derivatives[J]. Journal of China Pharmaceutical University, 2012, 43(5): 390-394.
    [7]HU Kun, XU Hua-jin, XIN Wen-qun, CHEN Xin, REN Jie. Synthesis and antitumor activity of nitrogen mustard derivatives of formononetin[J]. Journal of China Pharmaceutical University, 2012, 43(2): 113-119.
    [8]GAO Na-na, SUN Hong-bin. Synthesis and factor Xa inhibitory activity of rivaroxaban derivatives[J]. Journal of China Pharmaceutical University, 2011, 42(5): 392-399.
    [9]REN Jie, CHENG Hong, WANG Wei, HU Kun. Synthesis and antitumor activity of novel chrysin derivatives[J]. Journal of China Pharmaceutical University, 2011, 42(3): 206-212.
    [10]Synthesis and Antidiabetic Activity of Sulfonylcyanoguanidines[J]. Journal of China Pharmaceutical University, 1999, (4): 3-5.

Catalog

    Article views (710) PDF downloads (1173) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return